NEW YORK, May 21-Lynx Therapeutics will collaborate with Seattle's Institute for Systems Biology to study gene expression in prostate cancer, the company said today.
Lynx will apply its core "Massively Parallel Signature Sequencing" technology to identify genes that are differentially expressed in this cancer, and ISB will contribute other data. Together, the two will work to develop a systems biology approach to studying the disease.
Prostate cancer typically progresses from a localized androgen-dependent disease to a more dangerous metastatic form, but the biological details of this transformation are not well understood. The systems biology approach, according to Lynx, may provide new insights into the mechanisms of this disease.